UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

In re PHARMATRAK, INC. PRIVACY LITIGATION

*

Civil Action No. 00-11672-JLT

MDL Docket No. 1400

*

*

MEMORANDUM

November 6, 2003

TAURO, J.,

Plaintiffs, in a consolidated class action, sued Pharmatrak, Inc. and numerous pharmaceutical companies ("Defendants"), alleging that they secretly intercepted and accessed Plaintiffs' personal information through the use of computer "cookies" and other devices, in violation of state and federal law. This court granted summary judgment in favor of Defendants on all counts. Plaintiffs' sole claim on appeal was that Pharmatrak, Inc. ("Pharmatrak") violated Title I of the Electronic Communications Privacy Act³ ("EPCA"). The Court of Appeals remanded, finding that Pharmatrak "intercepted" personal information within the meaning of the EPCA, but that the intent element of the statute had not been adequately addressed by the

¹ For a detailed factual account of this action, see <u>In Re Pharmatrak, Inc. Privacy Litig.</u>, 220 F. Supp. 2d 4 (D. Mass. 2002).

² In re Pharmatrak, Inc., 220 F. Supp. 2d at 15.

³ 18 U.S.C. § 2510 et. seq.

⁴ See In Re Pharmatrak, Inc. Privacy Litig., 329 F.3d 9 (1st Cir. 2003).

⁵ The Court of Appeals held that Pharmatrak's behavior might be in violation of § 2511(a)(1) because its actions did not fall within the statute's consent exception. <u>In re Pharmatrak, Inc.</u>, 329 F.3d at 19-22. The EPCA provides for a private right of action, but it is subject the following statutory exception:

[&]quot;(d) It shall not be unlawful under this chapter for a person not acting under color of law

Parties ⁶

Defendants' motion for summary judgment on the EPCA claim is now before the court.

DISCUSSION

Under Federal Rule of Civil Procedure 56, summary judgment is appropriate "if the pleadings, depositions, answers to interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to a judgment as a matter of law." Rule 56 mandates summary judgment "after adequate time for discovery and upon motion, against a party who fails to make a showing sufficient to establish the existence of an element essential to that party's case, and on which that party will bear the burden of proof at trial."

The "party seeking summary judgment [must] make a preliminary showing that no genuine issue of material fact exists. Once the movant has made this showing, the nonmovant must contradict the showing by pointing to specific facts demonstrating that there is, instead, a

to intercept a wire, oral, or electronic communication where such person is a party to the communication or where one of the parties to the communication has given prior consent to such interception unless such communication is intercepted for the purpose of committing any criminal or tortious act " 18 U.S.C. § 2511(2)(d).

⁶ Title I of the EPCA, Interception of Electronic Communications, provides that: "Except as otherwise specifically provided in this chapter[,] any person who – (a) intentionally intercepts, endeavors to intercept, or procures any other person to intercept, any wire, oral, or electronic communication . . . shall be punished as provided in subsection (4) or shall be subject to suit as provided in subsection (5)." 18 U.S.C. § 2511(1)(a).

⁷Fed. R. Civ. P. 56(c).

⁸Celotex Corp. v. Catrett, 477 U.S. 317, 322 (1986).

trialworthy issue." The party opposing summary judgment must produce specific evidence of a material factual dispute. The First Circuit has noted that "[a] genuine issue of material fact does not spring into being simply because a litigant claims that one exists. Neither wishful thinking nor 'mere promise[s] to produce admissible evidence at trial' . . . nor conclusory responses unsupported by evidence . . . will serve to defeat a properly focused Rule 56 motion." ¹⁰

In this action, Defendants must make the initial showing that no genuine dispute of material fact exists and that the material facts demonstrate that they did not have the requisite intent under the EPCA. Once Defendants have met this burden, their motion will succeed unless Plaintiffs can point to specific evidence that indicates that Defendants did have the requisite intent.

To be criminally or civilly liable under the EPCA, the unlawful interception must have been intentional.¹¹ In its remand opinion, the Court of Appeals set out the legal standard to be applied in deciding the intent issue. The court noted that, in the 1986 amendment of the EPCA, Congress changed the state of mind requirement from "willful" to "intentional," defining "intentional" in its legislative history.¹²

As used in the Electronic Communications Privacy Act, the term "intentional" is narrower than the dictionary definition of "intentional." "Intentional" means more than that one voluntarily engaged in the conduct or caused the result. Such conduct or the causing of the result must have been the person's conscious objective.¹³

⁹Blackie v. Maine, 75 F.3d 716, 721 (1st Cir. 1996) (quotations omitted).

¹⁰Griggs-Ryan v. Smith, 904 F.2d 112, 115 (1st Cir. 1990) (citations omitted).

¹¹ 18 U.S.C. § 2511(1)(a).

¹² <u>Id.</u> at 23.

¹³ <u>Id.</u> (citing S. Rep. No. 99-541, at 23 (1986), <u>reprinted in</u> 1986 U.S.C.C.A.N. 3555, 3577).

The court went on to explain that by defining "intentional" in such a narrow manner, "Congress made clear that the purpose of the amendment was to underscore that inadvertent interceptions are not a basis for criminal or civil liability under the EPCA."¹⁴

Defendants argue that none of the facts indicates any kind of actionable intent on their part, and set forth three principal arguments in support of their summary judgement motion: (1) there was only a small amount of personal data actually found on Pharmatrak's computer servers; (2) errors from third parties caused the collection of the personal data; and (3) Defendants had no knowledge of the existence of the personal data until after Plaintiffs' filed their lawsuit. Each of these arguments is addressed <u>seriatim</u> below.

A. Only a Small Amount of Personal Data Was Actually Found

After Plaintiffs' computer expert conducted a thorough search of Pharmatrak's computers, as a result of this court's order to do so, he was able to assemble personal profiles on approximately 232 individuals. Pharmatrak's former Managing Director of Technology calculated that, between October, 1999 and February, 2001, "roughly 18.7 million unique Web users visited the tracked pharmaceutical company pages." Defendants contend that finding only 233 personal profiles from a potential list of 18.7 million (0.0012%) underscores their assertion that any transfer of personal information was inadvertent.

Plaintiffs try to avoid this logical inference by insinuating that Plaintiffs' expert completed only a partial inspection of Pharmatrak's computers.¹⁷ They wish to imply that a

¹⁴ Id.

 $^{^{15}}$ Macinta Supp. Aff. \P 17.

¹⁶ Id. at ¶¶ 17-18.

¹⁷ Pls'. Opp'n Defs'. Mot. Summ. J. at 8 n.11.

more thorough search of Pharmatrak's computers might uncover untold numbers of personal profiles. This is mere speculation at best. Pursuant to this court's order, Plaintiffs' expert was given unrestricted access to the hard drives of Pharmatrak's computer servers between December 17, 2001 and January 18, 2002. Plaintiffs now refer to that as "a mere *partial* inspection" without any explanation and without any basis for suggesting that more personal information is contained on the servers. Such unsupported and speculative assertions cannot defeat a motion for summary judgment.

B. Known Errors From Third Parties Caused the Collection of Personal Data

Defendants have provided undisputed descriptions of how pieces of personal information were transmitted to their servers. According to the Defendants, programming errors made by three different third parties caused these transmissions. One hundred sixty-six transmissions were the result of the inappropriate use of the GET method¹⁹ by two of the Defendant pharmaceutical companies, while the remaining sixty-seven occurred because of a mistake in Netscape's Navigator browser.²⁰ Because the transmissions were the result of circumstances

¹⁸ Id.

¹⁹ As the First Circuit explained, "Web servers use two methods to transmit information entered into online forms: the get method and the post method. The get method is generally used for short forms such as the 'Search' box at Yahoo! and other online search engines. The post method is normally used for longer forms and forms soliciting private information. When a server uses the get method, the information entered into the online form becomes appended to the next URL. For example, if a user enters 'respiratory problems' into the query box at a search engine, and the search engine transmits this information using the get method, then the words 'respiratory' and 'problems' will be appended to the query string at the end of the URL of the webpage showing the search results. By contrast, if a website transmits information via the post method, then that information does not appear in the URL." In re Pharmatrak, Inc. Privacy Litig., 329 F.3d 9, 15 (1st Cir. 2003).

²⁰ Macinta Supp. Aff. at ¶¶ 24-25, 26(A).

beyond their control, Defendants argue that they could not have intended to collect the information. Their assertion is supported by the First Circuit's definition of intentional: "Since one has no control over the existence of circumstances, one cannot 'intend' them."²¹

Plaintiffs do not dispute the descriptions of how the information was transmitted. But they attempt to circumvent the conclusion by arguing that, because Pharmatrak did not implement certain safeguards to prevent these sorts of transmissions, it must have intended to collect personal data.²² It is beside the point, however, whether such safeguards existed and whether they could have been used to prevent these transmissions. Even assuming that they did exist and could have been used, Pharmatrak would at most be liable under a theory of negligence, or even gross negligence. Neither is sufficient to satisfy the specific intent requirement under the EPCA.

Testimony by Plaintiffs' expert cannot change the situation. While experts may testify to facts from which a jury may find the requisite intent, no expert may opine about a criminal defendant's intent when, as here, intent is an element of the alleged crime.²³ Plaintiffs' expert would not be permitted to testify that Pharmatrak acted intentionally. He would only be able to lay out the facts as they have been detailed in Plaintiffs' opposition to this summary judgment motion.

C. Pharmatrak Had No Knowledge of the Personal Data Until After the Lawsuit Was Filed

Defendants' final argument in support of its summary judgment motion is that no one at

²¹ In re Pharmatrak, Inc., 329 F.3d at 23.

²² Pls'. Opp'n Defs'. Mot. Summ. J. at 9-11.

²³ <u>United States v. Valle</u>, 72 F.3d 210, 216 (1st Cir. 1995).

Pharmatrak even knew that it had collected any personal data during its years in operation.

Pharmatrak's former Chief of Technology stated in his deposition that "NETcompare was not

designed and there was no intent and there was no active designer intent to collect personal,

personally identifying, private or sensitive information about any particular individual."²⁴ He

also testified that he did not learn about the collection of personal information until April, 2002,

which was more than a year and a half after Plaintiffs filed this suit.²⁵

Plaintiffs offer no evidence to contradict these statements. They have provided no

testimony that indicates that anyone at Pharmatrak intentionally sought to collect personal data

through its NETcompare program.

CONCLUSION

For the foregoing reasons, Defendants' Motion for Summary Judgment by Pharmatrak

and Glocal on Plaintiffs' Claim Under 18 U.S.C. § 2511 [Docket # 294] is ALLOWED.

AN ORDER WILL ISSUE.

/S/ Joseph L. Tauro

United States District Judge

²⁴ Sonnenreich Dep. at 206-08.

²⁵ <u>Id.</u>

7

Publisher Information

Note* This page is not part of the opinion as entered by the court.

The docket information provided on this page is for the benefit of publishers of these opinions.

Attorneys

James D. Ardin Sidley & Austin 875 Third Avenue representing Pharmatrak, Inc., (Defendant)

New York, NY 10022 Assigned: 09/15/2000 LEAD

ATTORNEY ATTORNEY TO BE NOTICED
Assigned: 05/07/2001 LEAD ATTORNEY representing Pharmacia Corporation,

ATTORNEY TO BE NOTICED (Defendant)

Deborah E. Barnard Holland & Knight, LLP 10 St. representing Glaxo Wellcome PLC,

James Avenue Boston, MA 02116 617-523-2700 (Defendant)

617-523-6850 (fax) dbarnard@hklaw.com Assigned:

05/07/2001 LEAD ATTORNEY ATTORNEY TO BE

NOTICED

Smithline Beecham PLC,

Assigned: 05/18/2001 LEAD ATTORNEY representing Glaxo Wellcome PLC,

ATTORNEY TO BE NOTICED (Defendant)

Smithline Beecham PLC,

(Defendant)

George E. Barrett Barret Johnston & Parsley 217 representing Noah Blumofe (Plaintiff)

Second Avenue N Nashville, TN 37201-1601 615-

244-2202 Assigned: 05/15/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

David B. Bassett Hale & Dorr, LLP 60 State Street representing American Home Products Corp.

Boston, MA 02109 617-526-6259 617-526-5000 (Defendant)

(fax) david.bassett@haledorr.com Assigned:

10/10/2000 LEAD ATTORNEY ATTORNEY TO BE

NOTICED

Assigned: 05/07/2001 LEAD ATTORNEY representing American Home Products Corp.

ATTORNEY TO BE NOTICED

(Defendant) representing Pfizer, Inc., (Defendant)

100 Maiden Lane New York, NY 10038 212-504-

Dennis J. Block Cadwalader, Wickersham & Taft

5555 Assigned: 05/07/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

David A.P. Brower Wolf Haldenstein Adler Freeman representing Harris Perlman (Plaintiff)

& Herz 270 Madison Avenue New York, NY 11201

212-545-4600 Assigned: 05/15/2001 LEAD

ATTORNEY ATTORNEY TO BE NOTICED

Michael M. Buchman Milbert, Weiss, Bershad, Hynes representing Jim A. Darby (Plaintiff)

& Lerach, LLP One Pennsylvania Plaza New York,

NY 10119-0165 212-594-5300 Assigned:

05/15/2001 LEAD ATTORNEY ATTORNEY TO BE

NOTICED

Bryan L. Clobes Suite 1700 One Logan Square representing Noah Blumofe (Plaintiff)

18th and Cherry Streets Philadelphia, PA 19103

Assigned: 05/15/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

John J. Curtin Bingham McCutchen LLP 150 representing Pfizer, Inc., (Defendant)

Federal Street Boston, MA 02110 617-951-8000

Assigned: 05/07/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Assigned: 05/09/2001 LEAD ATTORNEY representing Pfizer, Inc., (Defendant)

ATTORNEY TO BE NOTICED

Donald N. David Fishbein, Badillo, Wagner & representing Pharmacia Corporation,

Harding 909 Third Avenue New York, NY 10022 (Defendant)

212-826-2000 Assigned: 05/07/2001 LEAD

ATTORNEY ATTORNEY TO BE NOTICED

William J. Doyle, II Milberg Weiss Bershad Hynes & representing Harris Perlman (Plaintiff)

Lerach LLP 401 B Street Suite 1700 San Diego, CA

92101 619-231-1058 619-231-7423 (fax)

BillDoy@milberg.com Assigned: 01/18/2002 LEAD

ATTORNEY ATTORNEY TO BE NOTICED

Jim A. Darby (Plaintiff)
Karen Gassman (Plaintiff)
Marcus Schroers (Plaintiff)
Noah Blumofe (Plaintiff)
Rob Barring (Plaintiff)
Robin McClary (Plaintiff)
Glocal Communications, LTD

Carmela N. Edmunds Dickstein, Shapiro & Morin representing

(Defendant)

2101 L Street, N.W. Washington, DC 20037 202-

785-9700 Assigned: 05/07/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Assigned: 04/10/2002 LEAD ATTORNEY representing Glocal Communications, LTD

ATTORNEY TO BE NOTICED (Defendant)

Matthew H. Feinberg & Kamholtz 125 representing Glocal Communications, LTD

Summer Street 6th Floor Boston, MA 02110 617- (Defendant)

526-0700 617-526-0701 (fax) mattfein@aol.com

Assigned: 09/15/2000 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Pharmacia Corporation,

(Defendant)

Assigned: 02/27/2001 LEAD ATTORNEY representing Pharmatrak, Inc., (Defendant)

ATTORNEY TO BE NOTICED

Nancy F. Gans Moulton & Gans, PC 33 Broad representing Karen Gassman (Plaintiff)

Street Suite 1100 Boston, MA 02109 617-369-7979

617-369-7980 (fax) nfgans@aol.com Assigned:

08/18/2000 LEAD ATTORNEY ATTORNEY TO BE

NOTICED

Assigned: 01/17/2002 LEAD ATTORNEY representing Noah Blumofe (Plaintiff)
Harris Perlman (Plaintiff)

ATTORNEY TO BE NOTICED

Jim A. Darby (Plaintiff)
Marcus Schroers (Plaintiff)
Rob Barring (Plaintiff)
Robin McClary (Plaintiff)

Glocal Communications, LTD Seymour Glanzer Dickstein, Shapiro, Morin & representing Oshinsky, LLP 2101 L Street, NW Washington, DC (Defendant) 20037 Assigned: 05/07/2001 LEAD ATTORNEY ATTORNEY TO BE NOTICED Pharmatrak, Inc., (Defendant) Louis Gottlieb Goodkind Labaton Rudoff & Sucharow representing Noah Blumofe (Plaintiff) 100 Park Avenue New York, NY 10017-5563 212-907-0700 Assigned: 05/15/2001 LEAD ATTORNEY ATTORNEY TO BE NOTICED Andrew M. Gschwind Bernstein Litowitz Berger & Noah Blumofe (Plaintiff) representing Grossmann 1285 Avenue of the Americas 33rd Floor New York, NY 10019 212-554-1400 212-554-1444 (fax) Assigned: 05/07/2001 TERMINATED: 11/05/2003 LEAD ATTORNEY ATTORNEY TO BE **NOTICED** Assigned: 05/15/2001 TERMINATED: 11/05/2003 representing Robin McClary (Plaintiff) LEAD ATTORNEY ATTORNEY TO BE NOTICED H. Peter Haveles Cadwalader, Wickersham & Taft Pfizer, Inc., (Defendant) representing 100 Maiden Lane New York, NY 10038 212-504-5555 Assigned: 05/07/2001 LEAD ATTORNEY ATTORNEY TO BE NOTICED Paul A. Hemmersbaugh Sidley & Austin 1722 I representing Pharmacia Corporation, Street, N.W. Washington, DC 20006 Assigned: (Defendant) 10/17/2001 LEAD ATTORNEY ATTORNEY TO BE **NOTICED** Matthew A. Kamholtz Feinberg & Kamholtz 125 representing Glocal Communications, LTD Summer Street 6th Floor Boston, MA 02110 617-(Defendant) 526-0700 617-526-0701 (fax) mattkamh@aol.com Assigned: 09/15/2000 LEAD ATTORNEY ATTORNEY TO BE NOTICED Pharmacia Corporation,

(Defendant)

Assigned: 02/27/2001 LEAD ATTORNEY representing Pharmatrak, Inc., (Defendant)

ATTORNEY TO BE NOTICED

Shannon Keniry Finkelstein, Thompson & Loughran representing Noah Blumofe (Plaintiff)

1055 Thomas Jefferson Street, NW Suite 601

Washington, DC 20007 202-337-8000 Assigned:

05/15/2001 LEAD ATTORNEY ATTORNEY TO BE

NOTICED

Daniel Krasner Wolf, Haldenstein, Adler, Freeman & representing Harris Perlman (Plaintiff)

Herz 270 Medison Ave. New York, NY 10016 212-

545-4600 Assigned: 05/15/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Marc C. Laredo & Smith LLP. 15 Broad representing Pharmatrak, Inc., (Defendant)

Street Ste. 600 Boston, MA 02109 617-367-7984

617-367-6475 (fax) laredo@laredosmith.com

Assigned: 09/15/2000 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Assigned: 10/11/2000 LEAD ATTORNEY representing Pharmacia Corporation,

ATTORNEY TO BE NOTICED

Assigned: 05/07/2001 LEAD ATTORNEY representing Pharmacia Corporation,

ATTORNEY TO BE NOTICED

William F. Lee Hale & Dorr, LLP 60 State Street representing American Home Products Corp.

Boston, MA 02109 617-526-6556 617-526-5000 (Defendant)

(fax) william.lee@haledorr.com Assigned:

10/10/2000 LEAD ATTORNEY ATTORNEY TO BE

NOTICED

Ralph T. Lepore, III Holland & Knight, LLP 10 St. representing Glaxo Wellcome PLC,

James Avenue Boston, MA 02116 617-523-2700 (Defendant)

617-523-6850 (fax) rlepore@hklaw.com Assigned:

05/07/2001 LEAD ATTORNEY ATTORNEY TO BE

NOTICED

Smithline Beecham PLC,

(Defendant)

(Defendant)

(Defendant)

Glaxo Wellcome PLC, Assigned: 05/18/2001 LEAD ATTORNEY representing ATTORNEY TO BE NOTICED (Defendant) Smithline Beecham PLC, (Defendant) Seth R. Lesser Bernstein, Litowitz, Berger & Noah Blumofe (Plaintiff) representing Grossman 1285 Avenue of the Americas New York, NY 10019 212-554-1400 Assigned: 05/07/2001 LEAD ATTORNEY ATTORNEY TO BE NOTICED Assigned: 05/15/2001 LEAD ATTORNEY Robin McClary (Plaintiff) representing ATTORNEY TO BE NOTICED Assigned: 07/19/2002 LEAD ATTORNEY representing Harris Perlman (Plaintiff) ATTORNEY TO BE NOTICED Jim A. Darby (Plaintiff) Karen Gassman (Plaintiff) Marcus Schroers (Plaintiff) Rob Barring (Plaintiff) Adam J. Levitt Wolf, Haldenstein, Adler, Freeman & representing Harris Perlman (Plaintiff) Herz, LLC 656 West Randolf Street Suite 500 W Chicago, IL 60661 Assigned: 05/15/2001 LEAD ATTORNEY ATTORNEY TO BE NOTICED Assigned: 11/26/2001 LEAD ATTORNEY Pharmatrak, Inc., (Defendant) representing ATTORNEY TO BE NOTICED Paul C. Llewellyn Kay, Scholer, Fierman, Hayes & representing Glaxo Wellcome PLC, Handler 425 Park Avenue New York, NY 10022 (Defendant) 212-836-8000 Assigned: 05/07/2001 LEAD ATTORNEY ATTORNEY TO BE NOTICED Smithline Beecham PLC, (Defendant) Marvin A. Miller Miller, Faucher and Cafferty, LLP representing Noah Blumofe (Plaintiff) 101 N. Main Street Suite 885 Ann Arbor, MI 48104 734-769-2144 Assigned: 05/15/2001 LEAD ATTORNEY ATTORNEY TO BE NOTICED Elizabeth M Mitchell Holland & Knight, LLP 10 St. Glaxo Wellcome PLC, representing James Avenue Boston, MA 02116 617-523-2700 (Defendant) 617-523-6850 (fax) emitchell@hklaw.com Assigned:

05/18/2001 LEAD ATTORNEY ATTORNEY TO BE

NOTICED

Smithline Beecham PLC,

(Defendant)

Stephen Moulton Moulton & Gans, PC 33 Broad

representing

Karen Gassman (Plaintiff)

Street 11th Floor Boston, MA 02109 617-369-7979

Assigned: 08/18/2000 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Douglas J. Nash Hiscock & Barclay LLP Financial representing

Noah Blumofe (Plaintiff)

American Home Products Corp.

Plaza 221 South Warren Street P.O.Box 4878

(Defendant)

Syracuse, NY 13221-4878 315-425-2828 315-472-

3059 (fax) dnash@hiscockbarclay.com Assigned:

10/10/2000 TERMINATED: 10/01/2003 LEAD

ATTORNEY ATTORNEY TO BE NOTICED

Richard F. O'Malley Sidley & Austin 875 Third

representing Pharmatr

Pharmatrak, Inc., (Defendant)

Avenue New York, NY 10022 212-906-2000

Assigned: 09/15/2000 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Assigned: 05/07/2001 LEAD ATTORNEY

representing

Pharmacia Corporation,

ATTORNEY TO BE NOTICED

Brian J. Robbins Robbins Umeda & Fink LLP Suite

representing

Harris Perlman (Plaintiff)

(Defendant)

2360 1010 Second Ave San Diego, CA 92101 619-

525-3990 Assigned: 06/19/2002 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Jim A. Darby (Plaintiff) Karen Gassman (Plaintiff) Marcus Schroers (Plaintiff) Noah Blumofe (Plaintiff)

Rob Barring (Plaintiff)
Robin McClary (Plaintiff)

Daniel S. Savrin Bingham McCutchen LLP 150

representing

Pfizer, Inc., (Defendant)

Federal Street Boston, MA 02110 617-951-8000

617-951-8736 (fax) daniel.savrin@bingham.com

Assigned: 05/07/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Mark D Smith Laredo & Smith, LLP 15 Broad St. representing Pharmatrak, Inc., (Defendant)

Suite 600 Boston, MA 02109 617-367-7984 617-

367-6475 (fax) smith@laredosmith.com Assigned:

09/15/2000 LEAD ATTORNEY ATTORNEY TO BE

NOTICED

Assigned: 10/11/2000 LEAD ATTORNEY representing Pharmacia Corporation,

ATTORNEY TO BE NOTICED (Defendant)

Assigned: 05/07/2001 LEAD ATTORNEY representing Pharmacia Corporation,

ATTORNEY TO BE NOTICED (Defendant)

David N. Sonnenreich The Sonnenreich Law Office, representing Glocal Communications, LTD

P.C. 802 Boston Building #9 Exchange Place Salt (Defendant)

Lake City, UT 84111 Assigned: 04/03/2002 LEAD

ATTORNEY ATTORNEY TO BE NOTICED

Pharmatrak, Inc., (Defendant)

Douglas G. Thompson Finkelstein, Thompson & representing Noah Blumofe (Plaintiff)

Loughran 1055 Thomas Jefferson Street, NW Suite

601 Washington, DC 20007 202-337-8000

Assigned: 05/15/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Daniel J. Tomasch Orrick, Herrington & Sutcliffe LLP representing American Home Products Corp.

666 Fifth Avenue New York, NY 10103 212-506- (Defendant)

5000 Assigned: 05/07/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Diana Weiss Orrick, Herrington & Sutcliffe LLP 666 representing American Home Products Corp.

Fifth Avenue New York, NY 10103 212-506-5000 (Defendant)

Assigned: 05/07/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Ann D. White MAGER WHITE & GOLDSTEIN LLP representing Noah Blumofe (Plaintiff)

One Pitcairn Place Suite 2400 165 Township Line

Road Jenkintown, PA 19046 215-481-0273

Assigned: 05/15/2001 LEAD ATTORNEY

ATTORNEY TO BE NOTICED

Frederic W. Yerman Kay, Scholer, Fierman, Hayes & representing Glaxo Wellcome PLC,

Handler 425 Park Avenue New York, NY 10022 (Defendant)

212-836-8000 Assigned: 05/07/2001 LEAD

ATTORNEY ATTORNEY TO BE NOTICED

Smithline Beecham PLC,

(Defendant)